BiotechTube

Abrocitinib

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prurigo Nodularis

Conditions

Prurigo Nodularis, Pruritus, Chronic Pruritus, Chronic Prurigo, Skin Diseases

Trial Timeline

Sep 9, 2021 → Jul 11, 2022

NCT ID
NCT05038982

About Abrocitinib

Abrocitinib is a phase 2 stage product being developed by Pfizer for Prurigo Nodularis. The current trial status is completed. This product is registered under clinical trial identifier NCT05038982. Target conditions include Prurigo Nodularis, Pruritus, Chronic Pruritus.

What happened to similar drugs?

1 of 7 similar drugs in Prurigo Nodularis were approved

Approved (1) Terminated (0) Active (6)
✅UpadacitinibAbbVieApproved
🔄Rocatinlimab + PlaceboAmgenPhase 3
🔄DupilumabSanofiPhase 3
🔄Ruxolitinib Cream + Vehicle CreamIncytePhase 3
🔄Povorcitinib + PlaceboIncytePhase 3
🔄Povorcitinib + PlaceboIncytePhase 3
🔄Ruxolitinib Cream + Vehicle CreamIncytePhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (9)

NCT IDPhaseStatus
NCT04564755Pre-clinicalCompleted
NCT05466578Pre-clinicalActive
NCT06899204Pre-clinicalRecruiting
NCT06807281Phase 3Recruiting
NCT06807268Phase 3Recruiting
NCT05721937Pre-clinicalRecruiting
NCT05689151Pre-clinicalRecruiting
NCT05391061Pre-clinicalRecruiting
NCT05038982Phase 2Completed

Competing Products

20 competing products in Prurigo Nodularis

See all competitors
ProductCompanyStageHype Score
Vixarelimab + PlaceboKiniksa PharmaceuticalsPhase 2
29
UpadacitinibAbbVieApproved
50
Pimecrolimus + Hydrocortisone + PimecrolimusNovartisPhase 2
35
Rocatinlimab + PlaceboAmgenPhase 3
44
Dupilumab SAR231893 (REGN668)SanofiPre-clinical
33
DupilumabSanofiPhase 3
47
DupilumabSanofiPre-clinical
33
DupilumabSanofiPre-clinical
30
Ruxolitinib Cream 1.5%IncytePhase 1
26
Ruxolitinib Cream + Vehicle CreamIncytePhase 3
37
INCB054707 + PlaceboIncytePhase 2
32
Povorcitinib + PlaceboIncytePhase 3
44
Povorcitinib + PlaceboIncytePhase 3
44
Ruxolitinib Cream + Vehicle CreamIncytePhase 3
37
CDX-0159 + Normal salineCelldex TherapeuticsPhase 1
23
barzolvolimabCelldex TherapeuticsPhase 2
33
nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BIDTrevi TherapeuticsPhase 2/3
32
nalbuphine HCl ERTrevi TherapeuticsPhase 2/3
32
Nalbuphine ER Tablets + Placebo TabletsTrevi TherapeuticsPhase 2/3
32
serlopitant + PlaceboVyne TherapeuticsPhase 2
25